LOS ANGELES
,
Aug. 28, 2024
/PRNewswire/ —
The Schall Law Firm
, a national shareholder rights litigation firm, highlights a class action lawsuit against MacroGenics, Inc. (“MacroGenics” or “the Company”)
MGNX for Securities Exchange Act violations.
Opportunity for Affected Investors
Investors who bought MacroGenics’ securities between March 7, 2024 and May 9, 2024, inclusive, have the chance to engage with the law firm until September 24, 2024.
Legal Representation and Rights
Shareholders who suffered losses are encouraged to reach out for legal counsel. The Schall Law Firm stands prepared to evaluate individual circumstances and provide necessary guidance at no cost.
Case Background and Allegations
Allegations suggest MacroGenics disseminated misleading information regarding the TAMARACK Phase 2 study. Subsequent updates revealed discrepancies, impacting investors’ understanding of the company’s performance.
Recover Losses
Affected parties are urged to consider participating in the lawsuit to seek recompense for incurred damages.
About The Schall Law Firm
The Schall Law Firm specializes in representing global investors in securities class actions, demonstrating expertise in shareholder rights litigation.
This publication may qualify as Attorney Advertising in particular regions as per governing laws and ethical standards.